Questcor (QCOR)
investors have had quite the ride over the past year. In addition to
positive clinical data, the company has seen encouraging success in
expanding its business in nephrology and rheumatology, but investors
will not soon forget the nearly two-thirds dive that the stock took on
word that Aetna (AET) was essentially dropping coverage on the company's only product.
There's
no doubt that Questcor is a risky stock. All of the company's revenue
comes from a single product that is off-patent (but very hard to
manufacture) and the company has no pipeline to speak of. Even so, the
shares appear undervalued with relatively little downside at present.
Please click here to continue:
Controversial Questcor Still Looks Like A Buy
No comments:
Post a Comment